$URGN
UroGen Pharma Ltd. Stock $urgn

$urgn Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000143774923031766 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$23.53M	$20.85M
YoY Change	30.06%	29.54%
Cost Of Revenue	$2.286M	$2.367M
YoY Change	1.02%	17.18%
Gross Profit	$21.24M	$18.49M
YoY Change	34.21%	31.31%
Gross Profit Margin	90.28%	88.65%
Selling, General & Admin	$24.55M	$21.76M
YoY Change	13.48%	14.07%
% of Gross Profit	115.57%	117.69%
Research & Development	$11.30M	$10.23M
YoY Change	-21.93%	-21.87%
% of Gross Profit	53.2%	55.34%
Depreciation & Amortization	$190.0K	$200.0K
YoY Change	-19.49%	0.0%
% of Gross Profit	0.89%	1.08%
Operating Expenses	$35.85M	$31.99M
YoY Change	-0.71%	-0.56%
Operating Profit	-$14.61M	-$13.50M
YoY Change	-27.97%	-25.36%
Interest Expense	-$2.860M	-$2.980M
YoY Change	1.53%	32.27%
% of Operating Profit
Other Income/Expense, Net	-$4.693M	$71.00K
YoY Change	-7.64%	-101.48%
Pretax Income	-$22.16M	-$21.89M
YoY Change	-21.36%	-12.87%
Income Tax	$3.854M	-$9.000K
% Of Pretax Income
Net Earnings	-$26.02M	-$21.88M
YoY Change	-7.9%	-15.3%
Net Earnings / Revenue	-110.57%	-104.93%
Basic Earnings Per Share		-$0.68
Diluted Earnings Per Share	-$0.72	-$0.68
COMMON SHARES
Basic Shares Outstanding	30.87M	30.28M
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$137.0M	$147.4M
YoY Change	37.02%	53.7%
Cash & Equivalents	$95.00M	$119.3M
Short-Term Investments	$41.97M	$28.11M
Other Short-Term Assets	$11.10M	$16.80M
YoY Change	-6.82%	47.47%
Inventory	$5.673M	$5.002M
Prepaid Expenses
Receivables	$15.44M	$12.85M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$169.2M	$182.1M
YoY Change	31.25%	49.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$689.0K	$823.0K
YoY Change	-46.88%	-45.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$4.502M	$6.500M
YoY Change
Other Assets	$2.038M	$2.050M
YoY Change	-25.62%	-17.04%
Total Long-Term Assets	$9.125M	$11.51M
YoY Change	35.95%	67.32%
TOTAL ASSETS
Total Short-Term Assets	$169.2M	$182.1M
Total Long-Term Assets	$9.125M	$11.51M
Total Assets	$178.3M	$193.6M
YoY Change	31.48%	50.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.514M	$4.041M
YoY Change	17.86%	58.78%
Accrued Expenses	$21.66M	$19.10M
YoY Change	34.9%	32.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$31.21M	$25.79M
YoY Change	30.51%	35.73%
LONG-TERM LIABILITIES
Long-Term Debt	$98.55M	$98.52M
YoY Change	1.04%	37.08%
Other Long-Term Liabilities	$113.8M	$111.3M
YoY Change	9.88%	10.32%
Total Long-Term Liabilities	$98.55M	$98.52M
YoY Change	1.04%	37.08%
TOTAL LIABILITIES
Total Short-Term Liabilities	$31.21M	$25.79M
Total Long-Term Liabilities	$98.55M	$98.52M
Total Liabilities	$243.5M	$235.6M
YoY Change	8.24%	22.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$679.3M	-$653.3M
YoY Change	17.71%	19.17%
Common Stock	$614.1M	$611.5M
YoY Change	25.88%	26.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$65.21M	-$41.99M
YoY Change
Total Liabilities & Shareholders Equity	$178.3M	$193.6M
YoY Change	31.48%	50.72%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$26.02M	-$21.88M
YoY Change	-7.9%	-15.3%
Depreciation, Depletion And Amortization	$190.0K	$200.0K
YoY Change	-19.49%	0.0%
Cash From Operating Activities	-$13.00M	-$17.30M
YoY Change	-40.25%	-1.77%
INVESTING ACTIVITIES
Capital Expenditures	$56.00K	$100.0K
YoY Change	330.77%	-165.36%
Acquisitions
YoY Change
Other Investing Activities	-$11.29M	$500.0K
YoY Change	-148.82%	-101.41%
Cash From Investing Activities	-$11.34M	$400.0K
YoY Change	-149.09%	-101.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	40.00K	116.1M
YoY Change	-99.84%	10443.14%
NET CHANGE
Cash From Operating Activities	-13.00M	-17.30M
Cash From Investing Activities	-11.34M	400.0K
Cash From Financing Activities	40.00K	116.1M
Net Change In Cash	-24.30M	99.18M
YoY Change	-190.93%	-290.72%
FREE CASH FLOW
Cash From Operating Activities	-$13.00M	-$17.30M
Capital Expenditures	$56.00K	$100.0K
Free Cash Flow	-$13.05M	-$17.40M
YoY Change	-40.03%	-0.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	20000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-21879000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-40913000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30854778
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30854778
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23129953
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23129953
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-138434000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1117000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-89361000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76228000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8413000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1133000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30900000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23100000
	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38079
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1460746
	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Alexander Park Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Princeton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08540
	dei	City Area Code CityAreaCode	646
	dei	Local Phone Number LocalPhoneNumber	768-9780
	dei	Security12b Title Security12bTitle	Ordinary Shares, par value NIS 0.01 per share
	dei	Trading Symbol TradingSymbol	URGN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30866320
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	119305000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55408000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	28114000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	44556000	usd
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	817000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	813000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12847000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12704000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	5002000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4325000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16038000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11101000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	182123000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	128907000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	823000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1297000	usd
CY2023Q3	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	225000	usd
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	223000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1905000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2452000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	6507000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2050000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2740000	usd
CY2023Q3	us-gaap	Assets Assets	193633000	usd
CY2022Q4	us-gaap	Assets Assets	135619000	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	14083000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12383000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8152000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8257000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3553000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3276000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	25788000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23916000	usd
CY2023Q3	urgn	Prepaid Forward Obligation PrepaidForwardObligation	107276000	usd
CY2022Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	98923000	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	98518000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	97537000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1026000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1586000	usd
CY2023Q3	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	3018000	usd
CY2022Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	3018000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	235626000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	224980000	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	84000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	63000	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	611389000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	487787000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-653332000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-577104000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-134000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-107000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-41993000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-89361000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	193633000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	135619000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20852000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16097000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59183000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46265000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	2367000	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	2020000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	7075000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	5391000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	18485000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	14077000	usd
	us-gaap	Gross Profit GrossProfit	52108000	usd
	us-gaap	Gross Profit GrossProfit	40874000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10230000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13093000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34312000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38429000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21755000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19071000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	68723000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61204000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13500000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18087000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-50927000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-58759000	usd
CY2023Q3	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	5479000	usd
CY2022Q3	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	4819000	usd
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	16047000	usd
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	16478000	usd
CY2023Q3	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	3815000	usd
CY2022Q3	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	2694000	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	11129000	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	5215000	usd
CY2023Q3	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	906000	usd
CY2022Q3	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	478000	usd
	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	1941000	usd
	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	604000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21888000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25122000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-76162000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-79848000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	709000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1066000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-21879000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-25831000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76228000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-80914000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-21879000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-25831000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76228000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-80914000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	20000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-99000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-27000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-130000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21859000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25930000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-76255000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-81044000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.89
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.56
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32298182
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22798263
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26358719
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22711686
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	18000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2224000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	48700000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	67358000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-41993000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2440000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-99000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-25831000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-63286000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	833000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6732000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	48700000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	67358000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-27000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-41993000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8212000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-130000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-80914000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-63286000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76228000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-80914000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	612000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	688000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
	us-gaap	Inventory Write Down InventoryWriteDown	615000	usd
	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	8714000	usd
	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	11019000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	622000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	93000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6732000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8212000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	981000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1077000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	669000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	679000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	677000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	645000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	143000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2288000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4937000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3104000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-690000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1000000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1700000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2746000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-105000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-323000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-704000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-766000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-856000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-63380000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-65807000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	35009000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	63009000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	45538000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	41202000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	138000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	241000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10391000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22048000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	833000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1133000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	70793000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	48700000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67358000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	160000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	116891000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	71766000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	63902000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16089000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56220000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	45587000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	120122000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29498000	usd
	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	122000	usd
	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	2165000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">1</em> </b>–<b> Business and Nature of Operations</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Nature of Operations</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Ltd. is an Israeli company incorporated in <em style="font: inherit;"> April 2004 (</em>“UPL”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma, Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in <em style="font: inherit;"> October 2015 </em>and began operating in <em style="font: inherit;"> February 2016 (</em>“UPI”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UPL and UPI (together the “Company”) is a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company’s <em style="font: inherit;">first</em> commercial product, <i>Jelmyto</i> (mitomycin) for pyelocalyceal solution, formerly known as UGN-<em style="font: inherit;">101,</em> clinical development of UGN-<em style="font: inherit;">102,</em> and raising capital to support and expand these activities.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> April 15, 2020, </em>the U.S. Food and Drug Administration (“FDA”) granted expedited approval for <i>Jelmyto</i>, a <em style="font: inherit;">first</em>-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (“low-grade UTUC”). <i>Jelmyto</i> consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release <i>RTGel</i> technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p>
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">2</em> </b>–<b> Basis of Presentation</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form <em style="font: inherit;">10</em>-Q and Article <em style="font: inherit;">10</em> of Regulation S-<em style="font: inherit;">X.</em> Accordingly, they do <em style="font: inherit;">not</em> include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are <em style="font: inherit;">not</em> necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does <em style="font: inherit;">not</em> include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022,</em> as filed with the U.S. Securities and Exchange Commission (“SEC”) on <em style="font: inherit;"> March 24, 2023.</em></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has experienced net losses since its inception and has an accumulated deficit o<span style="background-color:#ffffff;">f $653.3 </span>million and $577.1 million as of <em style="font: inherit;"> September 30, 2023</em> and <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022,</em> respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials. The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan. </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In accordance with the accounting guidance related to the presentation of financial statements, management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for the next <em style="font: inherit;">12</em> months from the date the financial statements are issued. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do <em style="font: inherit;">not</em> include any adjustments relating to the carrying amounts and classification of assets and liabilities that <em style="font: inherit;"> may </em>be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is expected to be impacted by its ability to raise additional capital to fund its operations, produce cash inflows from <i>Jelmyto</i> product sales and develop UGN-<em style="font: inherit;">102.</em> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> July </em><em style="font: inherit;">26,</em> <em style="font: inherit;">2023,</em> the Company entered into a private placement transaction with certain institutional and other accredited investors pursuant to which the Company agreed to sell its ordinary shares and pre-funded warrants to purchase ordinary shares to the investors, for aggregate gross proceeds of $120.0 million. See Note <em style="font: inherit;">14</em> for further discussion regarding the private placement transaction.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Based on the Company's cash, cash equivalents and marketable securities as of <em style="font: inherit;"> September </em><em style="font: inherit;">30,</em> <em style="font: inherit;">2023,</em> together with management’s cash flow projections, the Company believes that it has sufficient cash and cash equivalents to fund its operations beyond <em style="font: inherit;">one</em> year from the issuance of these financial statements. The Company will need to raise additional capital in the future. There can be <em style="font: inherit;">no</em> assurances that the Company will be able to secure such additional financing if at all, or on terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is <em style="font: inherit;">not</em> successful in obtaining sufficient funding, this could force us to delay, limit, or reduce our product development, commercialization efforts or other operations.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-653300000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-577100000	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	120000000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	37000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates. As applicable to the unaudited condensed consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.</p>
CY2023Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	153900000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentration of Credit Risk</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does <em style="font: inherit;">not</em> enter into any investment transaction for trading or speculative purposes.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s product sales are recognized through the Company's arrangement with a single customer, a <em style="font: inherit;">third</em>-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has <em style="font: inherit;">not</em> experienced any credit losses related to this customer and has <em style="font: inherit;">not</em> currently recognized any allowance for doubtful accounts.</p>
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	26000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	135000	usd
CY2023Q3	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	906000	usd
CY2022Q3	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	478000	usd
	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	1941000	usd
	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	604000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4041000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5527000	usd
CY2023Q3	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	2710000	usd
CY2022Q4	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	618000	usd
CY2023Q3	urgn	Accrued Clinical Expense AccruedClinicalExpense	1566000	usd
CY2022Q4	urgn	Accrued Clinical Expense AccruedClinicalExpense	2853000	usd
CY2023Q3	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1349000	usd
CY2022Q4	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1285000	usd
CY2023Q3	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	2601000	usd
CY2022Q4	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	1609000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1816000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	491000	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	14083000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12383000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	835000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	441000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1915000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	469000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	71000	usd
CY2023Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4948000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4676000	usd
CY2023Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1735000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2019000	usd
CY2023Q3	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	6683000	usd
CY2022Q4	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	6695000	usd
CY2023Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	34754000	usd
CY2023Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2023Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	134000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	34621000	usd
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments	55299000	usd
CY2023Q3	urgn	Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2023Q3	urgn	Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Losses Before Tax CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax	135000	usd
CY2023Q3	urgn	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	55165000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	32700000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	40	pure
CY2023Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	49635000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	44556000	usd
CY2023Q3	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	5529000	usd
CY2022Q4	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	0	usd
CY2023Q3	us-gaap	Investments Investments	55164000	usd
CY2022Q4	us-gaap	Investments Investments	44556000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4585000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4447000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3762000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3150000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	823000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1297000	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	700000	usd
CY2021Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	85713000	usd
CY2022	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	21559000	usd
CY2022	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	8349000	usd
CY2022Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	98923000	usd
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	16047000	usd
	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	7694000	usd
CY2023Q3	urgn	Prepaid Forward Obligation PrepaidForwardObligation	107276000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	225000	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	219000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	710000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	735000	usd
CY2023Q3	us-gaap	Sublease Income SubleaseIncome	56000	usd
CY2022Q3	us-gaap	Sublease Income SubleaseIncome	56000	usd
	us-gaap	Sublease Income SubleaseIncome	168000	usd
	us-gaap	Sublease Income SubleaseIncome	168000	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	13000	usd
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	16000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	51000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	52000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	182000	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	179000	usd
	us-gaap	Lease Cost LeaseCost	593000	usd
	us-gaap	Lease Cost LeaseCost	619000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1905000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2452000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1026000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1586000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	878000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	901000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	122000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2165000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M9D
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y11M12D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1016	pure
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1021	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	291000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	923000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	813000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	57000	usd
CY2023Q3	urgn	Lessee Operating Lease Liability To Be Paid After Year Three LesseeOperatingLeaseLiabilityToBePaidAfterYearThree	0	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2084000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	200000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1884000	usd
CY2023Q3	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	63000	usd
CY2023Q3	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	49000	usd
CY2023Q3	urgn	Lessor Operating Lease Payment To Be Received After Next Year LessorOperatingLeasePaymentToBeReceivedAfterNextYear	0	usd
CY2023Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	112000	usd
CY2022Q4	urgn	Accrued Sales Reserve AccruedSalesReserve	1437000	usd
	urgn	Sales Reserve Accruals SalesReserveAccruals	16500000	usd
	urgn	Sales Reserve Utilization SalesReserveUtilization	-13397000	usd
CY2023Q3	urgn	Accrued Sales Reserve AccruedSalesReserve	4540000	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30900000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23100000
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	120000000	usd
CY2023Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3781335
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1498367
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2224000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2440000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6732000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8212000	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	15600000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3000000	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	1100000	usd
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	0	usd

Files In Submission

Name	View Source	Status
0001437749-23-031766-index-headers.html	Edgar Link	pending
0001437749-23-031766-index.html	Edgar Link	pending
0001437749-23-031766.txt	Edgar Link	pending
0001437749-23-031766-xbrl.zip	Edgar Link	pending
ex_565605.htm	Edgar Link	pending
ex_565606.htm	Edgar Link	pending
ex_565607.htm	Edgar Link	pending
ex_565608.htm	Edgar Link	pending
ex_594504.htm	Edgar Link	pending
ex_595221.htm	Edgar Link	pending
ex_595222.htm	Edgar Link	pending
ex_595223.htm	Edgar Link	pending
ex_595224.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
urgn-20230930.xsd	Edgar Link	pending
urgn20230930_10q.htm	Edgar Link	pending
urgn-20230930_cal.xml	Edgar Link	unprocessable
urgn20230930_10q_htm.xml	Edgar Link	completed
urgn-20230930_def.xml	Edgar Link	unprocessable
urgn-20230930_lab.xml	Edgar Link	unprocessable
urgn-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$URGN
UroGen Pharma Ltd. Stock $urgn

2023 Q4 Form 10-Q Financial Statement

#000143774923031766 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN UroGen Pharma Ltd. Stock $urgn

2023 Q4 Form 10-Q Financial Statement

#000143774923031766 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN
UroGen Pharma Ltd. Stock $urgn